Bone Biologics (BBLG) S-1/A 4 Oct 22 IPO registration (amended) Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2022
Entity Addresses [Line Items]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	AMENDMENT NO. 2
Entity Registrant Name	BONE BIOLOGICS CORPORATION
Entity Central Index Key	0001419554
Entity Tax Identification Number	42-1743430
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2 Burlington Woods Drive
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Burlington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	781
Local Phone Number	552-4452
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	Bone Biologics Corporation
Entity Address, Address Line Two	2 Burlington Woods Drive
Entity Address, Address Line Three	Suite 100
Entity Address, City or Town	Burlington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	781
Local Phone Number	552-4452
Contact Personnel Name	Jeffrey Frelick

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets
Prepaid expenses	$ 204,359
Cash	5,454,522	6,675,365
Total assets	5,658,881	6,675,365
Current liabilities
Bank Overdraft			10,609
Accounts payable and accrued expenses	70,636	99,909	465,396
Current portion of notes payable – related party			11,712,179
Interest payable – related party			1,251,626
Deferred compensation			252,500
Total liabilities	70,636	99,909	13,692,310
Commitments and Contingencies
Stockholders’ equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at June 30, 2022 and December 31, 2021
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 10,350,579 and 10,350,574 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	10,350	10,350	12,273
Additional paid-in capital	77,212,305	77,040,713	55,160,339
Accumulated deficit	(71,634,410)	(70,475,607)	(68,864,922)
Total stockholders’ equity	5,588,245	6,575,456	(13,692,310)
Total liabilities and stockholders’ equity	$ 5,658,881	$ 6,675,365

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000	20,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	10,350,579	10,350,574	12,273,036
Common stock, shares outstanding	10,350,579	10,350,574	12,273,036

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues
Cost of revenues
Gross profit
Operating expenses
Research and development	17,600	2,016	54,000	47,516	82,044	340,672
General and administrative	451,704	229,865	1,103,203	365,289	1,019,432	484,342
Total operating expenses	469,304	231,881	1,157,203	412,805	1,101,476	825,014
Loss from operations	(469,304)	(231,881)	(1,157,203)	(412,805)	(1,101,476)	(825,014)
Other expenses
Interest expense, net – related party		(260,017)		(510,840)	(805,109)	(998,076)
Gain on forgiveness of deferred compensation					297,500
Total other income (expenses)					(507,609)	(998,076)
Loss before provision for income taxes	(469,304)	(491,898)	(1,157,203)	(923,645)	(1,609,085)	(1,823,090)
Provision for income taxes			1,600		1,600	1,600
Net Loss	$ (469,304)	$ (491,898)	$ (1,158,803)	$ (923,645)	$ (1,610,685)	$ (1,824,690)
Weighted average shares outstanding – basic and diluted	10,350,579	2,911,333	10,350,579	2,911,333	4,541,861	2,911,333
Loss per share – basic and diluted	$ (0.05)	$ (0.17)	$ (0.11)	$ (0.32)	$ (0.35)	$ (0.63)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2019	$ 12,273	$ 55,160,339	$ (67,040,232)	$ (11,867,620)
Balance, shares at Dec. 31, 2019	12,273,036
Net Loss			(1,824,690)	(1,824,690)
Balance at Dec. 31, 2020	$ 12,273	55,160,339	(68,864,922)	(13,692,310)
Balance, shares at Dec. 31, 2020	12,273,036
Net Loss			(431,747)	(431,747)
Balance at Mar. 31, 2021	$ 12,273	55,160,339	(69,296,669)	(14,124,057)
Balance, shares at Mar. 31, 2021	12,273,036
Balance at Dec. 31, 2020	$ 12,273	55,160,339	(68,864,922)	(13,692,310)
Balance, shares at Dec. 31, 2020	12,273,036
Net Loss				(923,645)
Balance at Jun. 30, 2021	$ 12,273	55,160,339	(69,788,567)	(14,615,955)
Balance, shares at Jun. 30, 2021	12,273,036
Balance at Dec. 31, 2020	$ 12,273	55,160,339	(68,864,922)	(13,692,310)
Balance, shares at Dec. 31, 2020	12,273,036
Fair value of vested stock options issued to employees and directors		207,035		207,035
Proceeds from sale of common stock units in public offering, net of offering costs $1,073,311	$ 1,510	6,857,333		6,858,843
Proceeds from sale of common stock units in public offering, net of offering costs $1,073,311, shares	1,510,455
Shares issued upon debt and accrued interest conversion	$ 5,929	14,816,006		14,821,935
Shares issued upon debt and accrued interest conversion, shares	5,928,774
Cancellation of collateral shares upon debt conversion	$ (9,362)			(9,362)
Cancellation of collateral shares upon debt conversion, Shares	(9,361,702)
Share adjustment for October 2021 stock split rounding
Share adjustment for October 2021 stock split rounding, shares	11
Net Loss			(1,610,685)	(1,610,685)
Balance at Dec. 31, 2021	$ 10,350	77,040,713	(70,475,607)	6,575,456
Balance, shares at Dec. 31, 2021	10,350,574
Balance at Mar. 31, 2021	$ 12,273	55,160,339	(69,296,669)	(14,124,057)
Balance, shares at Mar. 31, 2021	12,273,036
Net Loss			(491,898)	(491,898)
Balance at Jun. 30, 2021	$ 12,273	55,160,339	(69,788,567)	(14,615,955)
Balance, shares at Jun. 30, 2021	12,273,036
Balance at Dec. 31, 2021	$ 10,350	77,040,713	(70,475,607)	6,575,456
Balance, shares at Dec. 31, 2021	10,350,574
Fair value of vested stock options issued to employees and directors		152,844		152,844
Share adjustment for October 2021 stock split rounding
Share adjustment for October 2021 stock split rounding, shares	5
Net Loss			(689,499)	(689,499)
Balance at Mar. 31, 2022	$ 10,350	77,193,557	(71,165,106)	6,038,801
Balance, shares at Mar. 31, 2022	10,350,579
Balance at Dec. 31, 2021	$ 10,350	77,040,713	(70,475,607)	6,575,456
Balance, shares at Dec. 31, 2021	10,350,574
Net Loss				(1,158,803)
Balance at Jun. 30, 2022	$ 10,350	77,212,305	(71,634,410)	5,588,245
Balance, shares at Jun. 30, 2022	10,350,579
Balance at Mar. 31, 2022	$ 10,350	77,193,557	(71,165,106)	6,038,801
Balance, shares at Mar. 31, 2022	10,350,579
Fair value of vested stock options issued to employees and directors		18,748		18,748
Net Loss			(469,304)	(469,304)
Balance at Jun. 30, 2022	$ 10,350	$ 77,212,305	$ (71,634,410)	$ 5,588,245
Balance, shares at Jun. 30, 2022	10,350,579

Consolidated Statement of Sto_2

Consolidated Statement of Stockholders' Equity (Deficit) (Parenthetical)	12 Months Ended
	Dec. 31, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Payments of stock issuance costs	$ 1,073,311

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (1,158,803)	$ (923,645)	$ (1,610,685)	$ (1,824,690)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	171,592		207,035
Interest payable – related party		510,840	793,051	998,075
Gain on forgiveness of deferred compensation			(297,500)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(204,359)			6,682
Accounts payable and accrued expenses	(29,273)	(381,159)	(365,487)	333,000
Deferred compensation		30,000	45,000	60,000
Net cash used in operating activities	(1,220,843)	(763,964)	(1,228,586)	(426,933)
Cash flows from financing activities
Bank overdraft		(10,609)	(10,609)	10,609
Proceeds from sale of common stock units in public offering, net of offering costs			6,858,843
Proceeds from credit facilities – related party		779,011	1,055,717	392,179
Net cash provided by financing activities		768,402	7,903,951	402,788
Net increase (decrease) in cash	(1,220,843)	4,438	6,675,365	(24,145)
Cash, beginning of period	6,675,365			24,145
Cash, end of period	5,454,522	4,438	6,675,365
Supplemental information
Interest paid - related party			12,059
Income taxes paid	$ 1,600
Non-cash financing activities
Common shares issued upon conversion of Related Party Notes Payable and credit facilities			$ 14,821,935

The Company

The Company	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. The Company Bone Biologics Corporation (the “Company”) was incorporated under the laws of the State of Delaware on October 18, 2007 as AFH Acquisition X, Inc. Pursuant to a Merger Agreement, dated September 19, 2014, by and among the Company, its wholly-owned subsidiary, Bone Biologics Acquisition Corp., a Delaware corporation (“Merger Sub”), and Bone Biologics, Inc. Merger Sub merged with and into Bone Biologics Inc., with Bone Biologics Inc. remaining as the surviving corporation in the merger. Upon the consummation of the merger, the separate existence of Merger Sub ceased. On September 22, 2014, the Company officially changed its name to “Bone Biologics Corporation” to more accurately reflect the nature of its business and Bone Biologics, Inc. became a wholly owned subsidiary of the Company. Bone Biologics, Inc. was incorporated in California on September 9, 2004. We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBM. The NELL-1/DBM combination product is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The protein, as part of the UCB-1 technology platform, has been licensed exclusively for worldwide applications to us through a technology transfer from UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). UCLA TDG and the Company received guidance from the FDA that NELL-1/DBM will be classified as a combination product with a device lead. The production and marketing of the Company’s products and its ongoing research and development activities will be subject to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval process implemented by the FDA under the Food, Drug and Cosmetic Act. There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials. The Company’s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance that patents issued to or licensed by the Company will not be challenged, invalidated, or circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to the Company. On October 12, 2021, an amendment to our certificate of incorporation for a reverse split of the Company’s outstanding common stock at a ratio of 1 for 2.5 became effective. Going Concern and Liquidity The Company has no significant operating history and since inception to June 30, 2022 has incurred accumulated losses of approximately $ 71.6 9.5 1,158,803 1,220,843 On October 15, 2021, the Company completed a public offering generating net proceeds to the Company of $ 6,858,843 The Company will continue to attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company’s needs. If cash resources are insufficient to satisfy the Company’s on-going cash requirements, the Company will be required to scale back or discontinue its product development programs, or obtain funds if available (although there can be no certainties) through strategic alliances that may require the Company to relinquish rights to its technology, substantially reduce or discontinue its operations entirely. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing. For the past several years, we have depended on our relationship with Hankey Capital for working capital to fund our operations, which has been raised in the form of both debt and equity capital. Hankey Capital, directly and indirectly, controls approximately 70	1. The Company Bone Biologics Corporation (the “Company”) was incorporated under the laws of the State of Delaware on October 18, 2007 as AFH Acquisition X, Inc. Pursuant to a Merger Agreement, dated September 19, 2014, by and among the Company, its wholly-owned subsidiary, Bone Biologics Acquisition Corp., a Delaware corporation (“Merger Sub”), and Bone Biologics, Inc. Merger Sub merged with and into Bone Biologics Inc., with Bone Biologics Inc. remaining as the surviving corporation in the merger. Upon the consummation of the merger, the separate existence of Merger Sub ceased. On September 22, 2014, the Company officially changed its name to “Bone Biologics Corporation” to more accurately reflect the nature of its business and Bone Biologics, Inc. became a wholly owned subsidiary of the Company. Bone Biologics, Inc. was incorporated in California on September 9, 2004. We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBM. The NELL-1/DBM combination product is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The protein, as part of the UCB-1 technology platform, has been licensed exclusively for worldwide applications to us through a technology transfer from UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). UCLA TDG and the Company received guidance from the FDA that NELL-1/DBM will be classified as a combination product with a device lead. The production and marketing of the Company’s products and its ongoing research and development activities will be subject to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval process implemented by the FDA under the Food, Drug and Cosmetic Act. There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials. The Company’s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance that patents issued to or licensed by the Company will not be challenged, invalidated, or circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to the Company. On October 12, 2021, an amendment to our certificate of incorporation for a reverse split of the Company’s outstanding common stock at a ratio of 1 for 2.5 became effective. Going Concern and Liquidity The Company has no significant operating history and since inception to December 31, 2021 has incurred accumulated losses of approximately $ 70.5 6.5 1,610,685 1,228,586 On October 15, 2021, the Company completed a public offering (the “October 2021 Primary Offering”) of 1,510,455 0.001 6.30 5.25 6,858,843 226,568 226,568 90,627 6.30 5 The Company will continue to attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company’s needs. If cash resources are insufficient to satisfy the Company’s on-going cash requirements, the Company will be required to scale back or discontinue its product development programs, or obtain funds if available (although there can be no certainties) through strategic alliances that may require the Company to relinquish rights to its technology, substantially reduce or discontinue its operations entirely. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing. For the past several years, we have depended on our relationship with Hankey Capital for working capital to fund our operations, which has been raised in the form of both debt and equity capital. Hankey Capital, directly and indirectly, controls approximately 70 12,767,894 2,054,041

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The interim condensed consolidated financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under the accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes that the disclosures are adequate to make the information presented not misleading. The condensed consolidated balance sheet information as of December 31, 2021 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2022 (the “2021 Annual Report”). These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2021 and notes thereto included in the 2021 Annual Report. The results of operations for the six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the entire fiscal year ended December 31, 2022 or for any other period. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the accrual for potential liabilities, the valuation of stock options and warrants issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates. Impact of the Novel Coronavirus (COVID-19) on the Company’s Business Operations The global outbreak of the novel coronavirus (COVID-19) has led to severe disruptions in general economic activities worldwide, as businesses and governments have taken broad actions to mitigate this public health crisis. In light of the uncertain and continually evolving situation relating to the spread of COVID-19, this pandemic could pose a risk to the Company. The extent to which the coronavirus may impact the Company’s business operations will depend on future developments, which are highly uncertain and cannot be predicted at this time. The Company intends to continue to monitor the situation and may adjust its current business plans as more information and guidance become available. The coronavirus pandemic presents a challenge to medical facilities worldwide. As the Company’s clinical trials will be conducted on an outpatient basis, it is not currently possible to predict the full impact of this developing health crisis on such clinical trials, which could include delays in and increased costs of such clinical trials. Current indications from the clinical research organizations which will be conducting the clinical trials for the Company are that such clinical trials are being delayed or extended for several months as a result of the coronavirus pandemic. There is also significant uncertainty as to the effect that the coronavirus may have on the amount and type of financing available to the Company in the future. Fair Value of Financial Instruments The Company’s consolidated financial instruments are cash and accounts payable. The recorded values of cash and accounts payable approximate their values based on their short-term nature. The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on nine levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from embedded derivatives associated with certain warrants to purchase common stock. Stock Based Compensation ASC 718, Compensation – Stock Compensation Loss per Common Share The Company utilizes FASB ASC Topic No. 260, Earnings per Share 0 9,361,702 Since the effects of outstanding options, warrants, and the conversion of convertible debt are anti-dilutive for the period ended June 30, 2022 and 2021, shares of common stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of June 30, 2022 and 2021: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share June 30, 2022 2021 Warrants 1,827,650 33,304 Stock options 342,294 192,281 Convertible promissory notes - 4,996,476 Antidilutive securities, amount 2,169,944 5,222,061 New Accounting Standards Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements and related notes include activities of the Company and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the accrual for potential liabilities, the valuation of debt and equity instruments, stock options and warrants issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates. Impact of the Novel Coronavirus (COVID-19) on the Company’s Business Operations The global outbreak of the novel coronavirus (COVID-19) has led to severe disruptions in general economic activities worldwide, as businesses and governments have taken broad actions to mitigate this public health crisis. The coronavirus pandemic presents a challenge to medical facilities worldwide. As the Company’s clinical trials are conducted on an outpatient basis, it is not currently possible to predict the full impact of this developing health crisis on such clinical trials, which could include delays in and increased costs of such clinical trials. Current indications from the clinical research organizations conducting the clinical trials for the Company are that such clinical trials are being delayed or extended for several months as a result of the coronavirus pandemic. There is also significant uncertainty as to the effect that the coronavirus may have on the amount and type of financing available to the Company in the future. Fair Value of Financial Instruments The Company’s consolidated financial instruments are cash, accounts payable and notes payable. The recorded values of cash and accounts payable approximate their values based on their short-term nature. The fair value of convertible notes payable approximate their fair value since the current interest rates and terms on these obligations are the same as prevailing market rates. The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from embedded derivatives associated with certain warrants to purchase common stock. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. Research and Development Costs Research and development costs include, but are not limited to, payroll and other personnel expenses, consultants, expenses incurred under agreements with contract research and manufacturing organizations and animal clinical investigative sites and the cost to manufacture clinical trial materials. Costs related to research, design and development of products are charged to research and development expense as incurred. Patents and Licenses Effective April 9, 2019, the Company entered into an Amended and Restated Exclusive License Agreement dated as of March 21, 2019 (the “Amended License Agreement”) with the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). The Amended License Agreement amends and restates the Amended and Restated Exclusive License Agreement, dated as of June 19, 2017 (the “2017 Agreement”). The 2017 Agreement amended and restated the Exclusive License Agreement, effective March 15, 2006, between the Company and UCLA TDG, as amended by ten amendments. See Note 9 for commitments related to the Exclusive License Agreement. Patent expenses include costs to acquire the license of NELL-1, which was de minimis, and costs to file patent applications related to NELL-1. The Company expenses the costs incurred to file patent applications, all costs related to abandoned patent applications and maintenance costs, and these costs are included in general and administrative expenses. Costs associated with licenses acquired to be able to use products from third parties prior to receipt of regulatory approval to market the related products are also expensed. The Company’s licensed technologies may have alternative future uses in that they are enabling (or platform) technologies that can be the basis for multiple products that would each target a specific indication. Costs of acquisition of licenses are expensed. Concentration of Credit Risk and Other Risks and Uncertainties Cash balances are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Federal insurance coverage is $ 250,000 Stock Based Compensation ASC 718, Compensation – Stock Compensation Income Taxes Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes resulting from timing differences in recording of transactions for tax purposes and financial reporting purposes. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are received or settled. Valuation allowances are established when necessary to reduce deferred tax assets to amounts expected to be realized. The accounting provisions related to uncertain income tax positions require the Company to determine whether any tax position in all open years meets a more likely than not threshold of being sustained upon examination by the applicable taxing authority. The Company did not have any changes to its liability for uncertain tax positions as at December 31, 2021 and 2020. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. No such amounts are accrued as of December 31, 2021 and 2020. The Company recognizes the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination. The Company recognizes interest and/or penalties related to uncertain tax positions. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected in the period that such determination is made. The interest and penalties are recognized as other expense and not tax expense. The Company currently has no interest and penalties related to uncertain tax positions. Collateral Shares The Company accounts for the common shares issued as collateral for convertible promissory notes, whether upon original issuance or upon the required annual adjustment, as debt issuance costs in the form of a loan processing fee, which is determined by reference to the par value of the Company’s common stock, with a corresponding charge to operations when such collateral shares are issued. The collateral shares are subject to significant contractual restrictions limiting their sale or transfer. As these common shares have been issued to and are held by the lender, and are contingently returnable to the Company under certain conditions, such shares are considered as issued and outstanding on the Company’s balance sheet, but are not included in earnings per share calculations for all periods presented. In the event of an uncured event of default, the Company will record a charge to operations to recognize that the collateral shares are no longer owned or controlled by the Company, and such prospective charge to operations would be based on the fair market value of the collateral shares at that time, and which would be classified as a cost of debt capital and recognized as a charge to operations. As of December 31, 2021, all previously issued collateral shares have been returned to the common. Loss per Common Share The Company utilizes FASB ASC Topic No. 260, Earnings per Share 0 9,361,702 Since the effects of outstanding options, warrants, and the conversion of convertible debt are anti-dilutive for the years ended 2021 and 2020, shares of common stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of December 31, 2021 and 2020: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share December 31, 2021 2020 Warrants 1,827,650 91,841 Stock options 241,128 226,418 Convertible promissory notes - 4,684,872 2,068,778 5,003,131 New Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon adoption of ASU 2020-06, convertible debt proceeds, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. ASU 2020-06 will be effective January 1, 2024, and a cumulative-effect adjustment to the opening balance of retained earnings is required upon adoption. Early adoption is permitted. We early adopted ASU 2020-06 on January 1, 2021, using the modified retrospective approach. Adoption of the new standard did not affect any previously reported amounts. Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Notes Payable - Related Party

Notes Payable - Related Party	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes Payable - Related Party	3. Notes Payable - Related Party Hankey Capital LLC (Hankey Capital) Hankey Capital held certain convertible notes of the Company as discussed below. Don Hankey, the CEO and Chairman of Hankey Group, is our non-independent Chairman of the Board and a significant shareholder. Bret Hankey, the president of Hankey Capital, was a non-independent board member through October 13, 2021. The Hankey Group is an affiliate of Hankey Capital. Prior to January 1, 2019, the Company issued three convertible promissory notes in the aggregate amount of $ 9,000,000 December 31, 2021 4.0 8.5 1.00 9,000,000 7,659,574 The Company and Hankey Capital entered into agreements under which Hankey Capital provided credit facilities in an aggregate amount of $ 3,800,000 1.00 4.0 8.5 2,712,179 1,055,715 1,702,128 In connection with the October 2021 Primary Offering, Hankey Capital converted all the outstanding convertible notes and advances under the secured credit facilities ($ 12,767,894 2,054,041 9,361,702 Schedule of Notes Payable Note Type Issue Date Maturity Date Interest Rate December 31, 2021 December 31, 2020 First Secured Convertible Note 10/24/14 12/31/21 8.5 % $ - $ 5,000,000 Second Secured Convertible Note 5/4/15 12/31/21 8.5 % - 2,000,000 Third Secured Convertible Note 2/24/16 12/31/21 8.5 % - 2,000,000 First Credit Facility 7/24/18 12/31/21 8.5 % - 2,000,000 Second Credit Facility 9/19/19 12/31/21 8.5 % - 712,179 Notes payable $ - $ 11,712,179 Interest payable – related party on the above notes was $- 0 1,251,626 805,109 998,076

Stockholders_ Deficit

Stockholders’ Deficit	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Equity [Abstract]
Stockholders’ Deficit	3. Stockholders’ Deficit Preferred Stock The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 20,000,000 No Common Stock The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 100,000,000 10,350,579 10,350,574 Common Stock Warrants A summary of warrant activity for the period ended June 30, 2022 is presented below: Schedule of Warrant Activity Number of Weighted Weighted Subject to Exercise Warrants Price Life (Years) Outstanding as of December 31, 2021 1,827,650 $ 6.30 4.79 Granted – 2022 - - - Forfeited/Expired – 2022 - - - Exercised – 2022 - - - Outstanding as of June 30, 2022 1,827,650 $ 6.30 4.29 As of June 30, 2022, the Company had outstanding vested and unexercised Common Stock Warrants as follows: Schedule of Outstanding Vested and Unexercised Common Stock Warrants Date Issued Exercise Price Number of Expiration date October 2021 $ 6.30 1,737,023 October 13, 2026 October 2021 $ 6.30 90,627 October 13, 2026 Total outstanding warrants at June 30, 2022 1,827,650 Based on a fair market value of $ 1.40	4. Stockholders’ Deficit Preferred Stock The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 20,000,000 No Common Stock The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 100,000,000 10,350,574 12,273,036 2021 On October 15, 2021, the Company completed a public offering (the “October 2021 Primary Offering”) of 1,510,455 0.001 6.30 5.25 6,858,843 226,568 226,568 90,627 6.30 5 During October 2021, Hankey Capital converted all the outstanding convertible notes in accordance with the original term of the note agreements ($ 12,767,894 2,054,041 5,928,774 9,361,702 2020 During the year ended December 31, 2020 there were no shares issued. Common Stock Warrants A summary of warrant activity for the years ended December 31, 2021 and 2020 are presented below: Schedule of Warrant Activity Subject to Exercise Number of Warrants Weighted Average Exercise Price Weighted Average Life (Years) Outstanding as of December 31, 2019 204,855 $ 12.64 1.40 Granted – 2020 - - - Forfeited/Expired – 2020 (113,014 ) - - Exercised – 2020 - - - Outstanding as of December 31, 2020 91,841 $ 14.88 0.34 Granted – 2021 1,827,650 6.30 5.00 Forfeited/Expired – 2021 (91,841 ) - - Exercised – 2021 - - - Outstanding as of December 31, 2021 1,827,650 $ 6.30 4.79 As of December 31, 2021, the Company had outstanding vested and unexercised Common Stock Warrants as follows: Schedule of Outstanding Vested and Unexercised Common Stock Warrants Date Issued Exercise Price Number of Warrants Expiration date October 2021 $ 6.30 1,737,023 October 13, 2026 October 2021 $ 6.30 90,627 October 13, 2026 Total outstanding warrants at December 31, 2021 1,827,650 Based on a fair market value of $ 3.52

Stock-based Compensation

Stock-based Compensation	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	4. Stock-based Compensation 2015 Equity Incentive Plan The Company has 560,000 5% Awards may be granted under our 2015 Equity Incentive Plan to our employees, including officers, director or consultants, and our present or future affiliated entities. While we may grant incentive stock options only to employees, we may grant non-statutory stock options, stock appreciation rights, restricted stock purchase rights or bonuses, restricted stock units, performance shares, performance units and cash-based awards or other stock based awards to any eligible participant. The 2015 Equity Incentive Plan is administered by our compensation committee. Subject to the provisions of our 2015 Equity Incentive Plan, the compensation committee determines, in its discretion, the persons to whom, and the times at which, awards are granted, as well as the size, terms and conditions of each award. All awards are evidenced by a written agreement between us and the holder of the award. The compensation committee has the authority to construe and interpret the terms of our 2015 Equity Incentive Plan and awards granted under our 2015 Equity Incentive Plan. A summary of stock option activity for the period ended June 30, 2022, is presented below: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Subject to Exercise Options Price Life (Years) Value Outstanding as of December 31, 2021 241,128 $ 32.76 5.43 $ 9,445 Granted – 2022 101,166 3.67 4.07 - Forfeited/Expired – 2022 - - - - Exercised – 2022 - - - - Outstanding as of June 30, 2022 342,294 $ 21.76 4.80 $ - As of June 30, 2022, the Company had outstanding stock options as follows: Schedule of Outstanding Stock Options Date Issued Exercise Price Number of Expiration date August 2015 $ 39.75 41,624 December 27, 2025 September 2015 $ 39.75 8,000 December 27, 2025 November 2015 $ 39.75 48,986 December 27, 2025 December 2015 $ 39.75 2,228 December 27, 2025 January 2016 $ 39.75 51,032 January 9, 2026 May 2016 $ 51.25 10,766 May 26, 2026 September 2016 $ 51.25 3,973 May 31, 2026 January 2017 $ 51.25 2,142 January 1, 2027 January 2018 $ 49.25 1,566 January 1, 2028 January 2019 $ 2.35 21,964 January 1, 2029 October 2021 $ 5.25 48,847 October 26, 2031 January 2022 $ 3.52 26,166 January 1, 2032 January 2022 $ 3.72 50,000 January 1, 2024 January 2022 $ 3.72 25,000 January 3, 2024 Total outstanding options at June 30, 2022 342,294 The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value ( i.e. There were 101,166 171,592 During the six month period ended June 30, 2022 and 2021, the Company had stock-based compensation expense of $ 171,592 0 The Company utilized the Black-Scholes option-pricing model. The assumptions used for the periods ended June 30, 2022 and 2021 are as follows: Schedule of Assumptions Using Black-Scholes Option Pricing Model June 30, 2022 June 30, 2021 Risk free interest rate 0.39% 1.279 % - % Expected life (in years) 1.00 5.37 - Expected Volatility 96.24% 112.54 % - % Expected dividend yield - % - % A summary of the changes in the Company’s non-vested options during the six month period ended June 30, 2022, is as follows: Schedule of Stock Options Non-vested Number of Non- Weighted Average Non-vested at December 31, 2021 - $ - Granted in 2022 101,166 $ 1.77 Forfeited in 2022 - $ - Vested in 2022 (101,166 ) $ 1.77 Non-vested at June 30, 2022 - $ - Exercisable at June 30, 2022 342,294 $ 21.81 Outstanding at June 30, 2022 342,294 $ 21.81 As of June 30, 2022, there was no	5. Stock-based Compensation 2015 Equity Incentive Plan The Company has 560,000 5 Awards may be granted under our 2015 Equity Incentive Plan to our employees, including officers, director or consultants, and our present or future affiliated entities. While we may grant incentive stock options only to employees, we may grant non-statutory stock options, stock appreciation rights, restricted stock purchase rights or bonuses, restricted stock units, performance shares, performance units and cash-based awards or other stock based awards to any eligible participant. The 2015 Equity Incentive Plan is administered by our compensation committee. Subject to the provisions of our 2015 Equity Incentive Plan, the compensation committee determines, in its discretion, the persons to whom, and the times at which, awards are granted, as well as the size, terms and conditions of each award. All awards are evidenced by a written agreement between us and the holder of the award. The compensation committee has the authority to construe and interpret the terms of our 2015 Equity Incentive Plan and awards granted under our 2015 Equity Incentive Plan. A summary of stock option activity for the years ended December 31, 2021 and 2020 are presented below: Schedule of Stock Option Activity Subject to Exercise Number of Options Weighted Average Exercise Price Weighted Average Life (Years) Aggregate Intrinsic Value Outstanding as of December 31, 2019 226,418 $ 41.08 6.56 $ - Granted – 2020 - - - - Forfeited/Expired – 2020 - - - - Exercised – 2020 - - - - Outstanding as of December 31, 2020 226,418 $ 37.00 4.65 $ - Outstanding as of December 31, 2020 226,418 $ 37.00 4.65 $ - Granted – 2021 48,847 4.24 10.00 - Forfeited/Expired – 2021 (34,137 ) 40.48 - - Exercised – 2021 - - - - Outstanding as of December 31, 2021 241,128 $ 32.76 5.43 $ 9,445 As of December 31, 2021, the Company had outstanding stock options as follows: Schedule of Outstanding Stock Options Date Issued Exercise Price Number of Options Expiration date August 2015 $ 39.75 41,624 December 27, 2025 September 2015 $ 39.75 8,000 December 27, 2025 November 2015 $ 39.75 48,986 December 27, 2025 December 2015 $ 39.75 2,228 December 27, 2025 January 2016 $ 39.75 51,032 January 9, 2026 May 2016 $ 51.25 10,766 May 26, 2026 September 2016 $ 51.25 3,973 May 31, 2026 January 2017 $ 51.25 2,142 January 1, 2027 January 2018 $ 49.25 1,566 January 1, 2028 January 2019 $ 2.35 21,964 January 1, 2029 October 2021 $ 5.25 48,847 October 26, 2031 Total outstanding options at December 31, 2021 241,128 The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value ( i.e. There were 48,847 207,035 no During the years ended December 31, 2021 and 2020, the Company had stock-based compensation expense of $ 207,035 0 The Company utilized the Black-Scholes option-pricing model. The assumptions used for the years ended December 31, 2021 and 2020 are as follows: Schedule of Assumptions Using Black-Scholes Option Pricing Model December 31, 2021 December 31, 2020 Risk free interest rate 1.21 % - % Expected life (in years) 2 10 - Expected Volatility 113.93 % - % Expected dividend yield 0 % 0 %

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes The provision for income taxes consists of the following: Schedule of Provision for Income Taxes Year Ended December 31, 2021 December 31, 2020 Current: Federal $ - $ - State 1,600 1,600 Total current 1,600 1,600 Deferred: Federal - - State - - Total deferred - - Provision for income taxes $ 1,600 $ 1,600 The components of deferred tax assets and liabilities consist of the following: Schedule of Deferred Tax Assets and Liabilities December 31, 2021 December 31, 2020 Deferred tax assets Net operating losses $ 9,189,000 $ 8,749,000 Accrued expenses 693,000 693,000 R&D credits 624,000 619,000 Stock compensation 8,287,000 8,287,000 Total 18,793,000 18,348,000 Less: Valuation allowance (18,793,000 ) (18,348,000 ) Deferred tax assets $ - $ - The Company’s federal and state net operating loss carryforwards at December 31, 2021 and 2020 were approximately $ 29,662,000 29,860,000 The Company reviews its deferred tax assets for realization based upon historical taxable income, prudent and feasible tax planning strategies, the expected timing of the reversals of existing temporary differences and expected future taxable income. The Company has concluded that it is more likely than not that the deferred tax assets will not be realized. Accordingly, the Company has recorded a valuation allowance against the net deferred tax assets in the amount of $ 18,793,000 445,000 The effective tax rate differs from the statutory tax rate principally due to the change in valuation allowance, nondeductible permanent differences, credits, and state income taxes. A reconciliation of the federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2021 and 2020 is as follows: Schedule of Income Tax Effective Tax Rate December 31, 2021 December 31, 2020 Statutory federal income tax rate 21.0 % 21.0 % State taxes, net of federal tax benefit 6.2 % 6.9 % Nondeductible permanent items (0.1 )% (0.2 )% Deferred tax rate change - % - % Research and development credit 0.3 % 1.2 % Change in valuation allowance (27.4 )% (28.9 )% Income tax provision 0.0 % 0.0 % The Company’s effective tax rate is 0 The Company files tax returns for U.S. Federal, State of Massachusetts, and State of California. The Company is not currently subject to any income tax examinations. Since the Company’s inception, the Company had incurred losses from operations, which generally allows all tax years to remain open.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions Hankey Capital LLC (Hankey Capital) Hankey Capital held certain convertible notes of the Company as discussed in Note 3. Don Hankey, the CEO and Chairman of Hankey Group, is our non-independent Chairman of the Board and a significant shareholder. Bret Hankey, the president of Hankey Capital, was a non-independent board member through October 13, 2021. The Hankey Group is an affiliate of Hankey Capital.

Deferred Compensation

Deferred Compensation	12 Months Ended
	Dec. 31, 2021
Deferred Compensation
Deferred Compensation	8. Deferred Compensation Pursuant to an October 2016 Note Purchase Agreement, the Company’s management had agreed to defer 20 5,000,000 252,500 45,000 297,500 297,500 As of December 31, 2021 and 2020, deferred compensation was $- 0 252,500

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies UCLA TDG Exclusive License Agreement Effective April 9, 2019, the Company entered into an Amended and Restated Exclusive License Agreement dated as of March 21, 2019 and amended through three sets of amendments including a third amendment effective May 9, 2022 (as so amended the “Amended License Agreement”) with the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). The Amended License Agreement amends and restates the Amended and Restated Exclusive License Agreement, dated as of June 19, 2017 (the “2017 Agreement”). The 2017 Agreement amended and restated the Exclusive License Agreement, effective March 15, 2006, between the Company and UCLA TDG, as amended by ten amendments. Under the terms of the Amended License Agreement, UCLA TDG has continued to grant the Company exclusive rights to develop and commercialize NELL-1 (the “Licensed Product”) for spinal fusion, osteoporosis and trauma applications. The Licensed Product is a recombinant human protein growth factor that is essential for normal bone development. We have agreed to pay an annual maintenance fee to UCLA TDG of $ 10,000 3.0% 50,000 250,000 0.333% 10% 20% We are obligated to make the following milestone payments to UCLA TDG for each Licensed Product or Licensed Method: ● $ 100,000 ● $ 250,000 ● $ 500,000 ● $ 1,000,000 We are also obligated pay to UCLA TDG a fee (the “Diligence Fee”) of $ 8,000,000 ● Due upon cumulative Net Sales equaling $50,000,000 following the Triggering Sale Date - $2,000,000 ● Due upon cumulative Net Sales equaling $100,000,000 following the Triggering Sale Date - $2,000,000 ● Due upon cumulative Net Sales equaling $200,000,000 following the Triggering Sale Date - $4,000,000 The Company’s obligation to pay the Diligence Fee will survive termination or expiration of the agreement and the Company is prohibited from assigning, selling, or otherwise transferring any of its assets related to any Licensed Product unless the Company’s foregoing Diligence Fee obligation is assigned, sold, or transferred along with such assets, or unless the Company pays UCLA TDG the Diligence Fee within ten (10) days of such assignment, sale or other transfer of such rights to any Licensed Product. We are also obligated to pay UCLA TDG a cash milestone payment within thirty (30) days of a Liquidity Event (including a Change of Control Transaction and a payment election by UCLA TDG exercisable after December 22, 2016) such payment to equal the greater of: ● $ 500,000 ● 2% We are obligated to diligently proceed with developing and commercializing licensed products under UCLA TDG patents set forth in the Amended License Agreement. UCLA TDG has the right to either terminate the license or reduce the license to a non-exclusive license if we do not meet certain diligence milestone deadlines set forth in the Amended License Agreement. We must reimburse or pre-pay UCLA TDG for patent prosecution and maintenance costs incurred during the term of the Amended License Agreement. We have the right to bring infringement actions against third party infringers of the Amended License Agreement, UCLA TDG may join voluntarily, at its own expense, or, at our expense, be joined involuntarily to the action. We are required to indemnify UCLA TDG against any third party claims arising out of our exercise of the rights under the Amended License Agreement or any sublicense. Payments to UCLA TDG under the Amended License Agreement for the six months ended June 30, 2022 and 2021 were $ 10,000 45,500 Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows. In July 2019, Dr. Bessie (Chia) Soo and Dr. Kang (Eric) Ting (“Plaintiffs”) filed a complaint (the “Complaint”) in federal court in Massachusetts against the Company, Bruce Stroever (“Stroever”), John Booth (“Booth”), Stephen LaNeve (“LaNeve”, and together with Stroever and Booth, the “Individual Defendants”), and MTF Biologics (f/k/a The Musculoskeletal Transplant Foundation, Inc.) (“MTF”). The Complaint alleges claims for breach of contract against the Company and tortious interference with contract against the Individual Defendants and MTF arising from the termination of the Professional Service Agreements, dated as of January 8, 2016, between the Company and each of the Plaintiffs. The Individual Defendants have been sued for actions taken by them in connection with their service to the Company as directors and/or officers of the Company. As such, the Company has certain indemnification obligations to the Individual Defendants. The Company and the Individual Defendants intend to vigorously defend against the allegations in the Complaint. Based on the early stage of the litigation, it is not possible to estimate the amount or range of any possible loss arising from the expenditure of defense fees, a judgment or settlement of the matter.	9. Commitments and Contingencies UCLA TDG Exclusive License Agreement Effective April 9, 2019, the Company entered into an Amended and Restated Exclusive License Agreement dated as of March 21, 2019 (as so amended the “Amended License Agreement”) with the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). The Amended License Agreement amends and restates the Amended and Restated Exclusive License Agreement, dated as of June 19, 2017 (the “2017 Agreement”). The 2017 Agreement amended and restated the Exclusive License Agreement, effective March 15, 2006, between the Company and UCLA TDG, as amended by ten amendments. Under the terms of the Amended License Agreement, the Regents have continued to grant the Company exclusive rights to develop and commercialize NELL-1 (the “Licensed Product”) for spinal fusion, osteoporosis and trauma applications. The Licensed Product is a recombinant human protein growth factor that is essential for normal bone development. We have agreed to pay an annual maintenance fee to UCLA TDG of $ 10,000 3.0 50,000 250,000 0.333 10 20 We are obligated to make the following milestone payments to UCLA TDG for each Licensed Product or Licensed Method: ● $ 100,000 ● $ 250,000 ● $ 500,000 ● $ 1,000,000 We are also obligated to pay UCLA TDG a cash milestone payment within thirty (30) days of a Liquidity Event (including a Change of Control Transaction and a payment election by UCLA TDG exercisable after December 22, 2016, such payment to equal the greater of: ● $ 500,000 ● 2 As of December 31, 2021, none of the above milestones has been met. We are obligated to diligently proceed with developing and commercializing licensed products under UCLA patents set forth in the Amended License Agreement. UCLA TDG has the right to either terminate the license or reduce the license to a non-exclusive license if we do not meet certain diligence milestone deadlines set forth in the Amended License Agreement. We must reimburse or pre-pay UCLA TDG for patent prosecution and maintenance costs incurred during the term of the Amended License Agreement. We have the right to bring infringement actions against third party infringers of the Amended License Agreement, UCLA TDG may join voluntarily, at its own expense, or, at our expense, be joined involuntarily to the action. We are required to indemnify UCLA TDG against any third party claims arising out of our exercise of the rights under the Amended License Agreement or any sublicense. On August 13, 2020 the Company and UCLA TDG entered into a First Amendment to the Amended and Restated License Agreement pursuant to which the due dates for certain Development Milestones were updated to better reflect delays caused by the COVID-19 Pandemic and to address the Company’s failure to pay certain amounts with regard to patent prosecution, cost reimbursement, maintenance fees, and late fees, and in connection therewith, a revised payment schedule was set forth. On June 30, 2021 the Company and UCLA TDG entered into a Second Amendment to the Amended and Restated License Agreement pursuant to which the due dates for certain Development Milestones was updated to better reflect delays caused by the COVID-19 Pandemic. Payments to UCLA TDG under the Amended License Agreement for the years ended December 31, 2021 and 2020 were $ 45,500 102,293 Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows. In July 2019, Dr. Bessie (Chia) Soo and Dr. Kang (Eric) Ting (“Plaintiffs”) filed a complaint (the “Complaint”) in federal court in Massachusetts against the Company, Bruce Stroever (“Stroever”), John Booth (“Booth”), Stephen LaNeve (“LaNeve”, and together with Stroever and Booth, the “Individual Defendants”), and MTF Biologics (f/k/a The Musculoskeletal Transplant Foundation, Inc.) (“MTF”). The Complaint alleges claims for breach of contract against the Company and tortious interference with contract against the Individual Defendants and MTF arising from the termination of the Professional Service Agreements, dated as of January 8, 2016, between the Company and each of the Plaintiffs. The Individual Defendants have been sued for actions taken by them in connection with their service to the Company as directors and/or officers of the Company. As such, the Company has certain indemnification obligations to the Individual Defendants. The Company and the Individual Defendants intend to vigorously defend against the allegations in the Complaint. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of any possible loss arising from the expenditure of defense fees, a judgment or settlement of the matter.

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	6. Subsequent Events On August 23, 2022, the Company issued to three (3) of our non-employee independent directors each 36,845	10. Subsequent Events On December 17, 2021, Bone Biologics Corporation (the “Company”) entered into a revised Employment Agreement (the “Employment Agreement”) with Deina H. Walsh, the Company’s Chief Financial Officer (“CFO) and principal accounting officer. The Employment Agreement is effective January 3, 2022. Ms. Walsh has served as the Company’s CFO since November 4, 2014. Under the terms of the Employment Agreement, Ms. Walsh will serve as the Company’s CFO at-will and not for any specified period and may be terminated at any time with or without cause. Her base salary will be $ 200,000 25 The annual bonus, if any, shall be paid on or before March 15th of the calendar year following the year in which it is considered earned. The actual annual bonus paid may be more or less than twenty-five percent (25%) of Ms. Walsh’s base salary Ms. Walsh will receive a stock option grant whereby she is entitled to 25,000 On January 1, 2022, Mr. Frelick received a stock option grant whereby he is entitled to 50,000 On January 1, 2022, pursuant to our Non-Employee Director Compensation Policy, 26,166 On March 3, 2022, Bone Biologics Corporation (the “Company”) entered into a Supply and Development Support Agreement (the “Agreement”) with Musculoskeletal Transplant Foundation, Inc. (“MTF”). Under the Agreement, MTF agrees to be the exclusive supplier of demineralized bone matrix (“DBM”) to the Company for use with Nell-1 and MTF will provide reasonable development support to the Company for the development of Nell-1 with DBM as a carrier. The Agreement is in effect for a period of five years and may be extended for one (1) or more years upon mutual agreement of the Company and MTF. The Agreement also includes provisions relating to, among others, delivery, inspection procedures, warranties, quality management, compliance, forecasts, intellectual property rights, indemnification, and confidentiality.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The interim condensed consolidated financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under the accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes that the disclosures are adequate to make the information presented not misleading. The condensed consolidated balance sheet information as of December 31, 2021 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2022 (the “2021 Annual Report”). These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2021 and notes thereto included in the 2021 Annual Report. The results of operations for the six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the entire fiscal year ended December 31, 2022 or for any other period.	Basis of Presentation The accompanying consolidated financial statements and related notes include activities of the Company and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the accrual for potential liabilities, the valuation of stock options and warrants issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates.	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the accrual for potential liabilities, the valuation of debt and equity instruments, stock options and warrants issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates.
Impact of the Novel Coronavirus (COVID-19) on the Company’s Business Operations		Impact of the Novel Coronavirus (COVID-19) on the Company’s Business Operations The global outbreak of the novel coronavirus (COVID-19) has led to severe disruptions in general economic activities worldwide, as businesses and governments have taken broad actions to mitigate this public health crisis. The coronavirus pandemic presents a challenge to medical facilities worldwide. As the Company’s clinical trials are conducted on an outpatient basis, it is not currently possible to predict the full impact of this developing health crisis on such clinical trials, which could include delays in and increased costs of such clinical trials. Current indications from the clinical research organizations conducting the clinical trials for the Company are that such clinical trials are being delayed or extended for several months as a result of the coronavirus pandemic. There is also significant uncertainty as to the effect that the coronavirus may have on the amount and type of financing available to the Company in the future.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s consolidated financial instruments are cash and accounts payable. The recorded values of cash and accounts payable approximate their values based on their short-term nature. The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on nine levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from embedded derivatives associated with certain warrants to purchase common stock.	Fair Value of Financial Instruments The Company’s consolidated financial instruments are cash, accounts payable and notes payable. The recorded values of cash and accounts payable approximate their values based on their short-term nature. The fair value of convertible notes payable approximate their fair value since the current interest rates and terms on these obligations are the same as prevailing market rates. The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from embedded derivatives associated with certain warrants to purchase common stock. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.
Research and Development Costs		Research and Development Costs Research and development costs include, but are not limited to, payroll and other personnel expenses, consultants, expenses incurred under agreements with contract research and manufacturing organizations and animal clinical investigative sites and the cost to manufacture clinical trial materials. Costs related to research, design and development of products are charged to research and development expense as incurred.
Patents and Licenses		Patents and Licenses Effective April 9, 2019, the Company entered into an Amended and Restated Exclusive License Agreement dated as of March 21, 2019 (the “Amended License Agreement”) with the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). The Amended License Agreement amends and restates the Amended and Restated Exclusive License Agreement, dated as of June 19, 2017 (the “2017 Agreement”). The 2017 Agreement amended and restated the Exclusive License Agreement, effective March 15, 2006, between the Company and UCLA TDG, as amended by ten amendments. See Note 9 for commitments related to the Exclusive License Agreement. Patent expenses include costs to acquire the license of NELL-1, which was de minimis, and costs to file patent applications related to NELL-1. The Company expenses the costs incurred to file patent applications, all costs related to abandoned patent applications and maintenance costs, and these costs are included in general and administrative expenses. Costs associated with licenses acquired to be able to use products from third parties prior to receipt of regulatory approval to market the related products are also expensed. The Company’s licensed technologies may have alternative future uses in that they are enabling (or platform) technologies that can be the basis for multiple products that would each target a specific indication. Costs of acquisition of licenses are expensed.
Concentration of Credit Risk and Other Risks and Uncertainties		Concentration of Credit Risk and Other Risks and Uncertainties Cash balances are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Federal insurance coverage is $ 250,000
Stock Based Compensation	Stock Based Compensation ASC 718, Compensation – Stock Compensation	Stock Based Compensation ASC 718, Compensation – Stock Compensation
Income Taxes		Income Taxes Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes resulting from timing differences in recording of transactions for tax purposes and financial reporting purposes. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are received or settled. Valuation allowances are established when necessary to reduce deferred tax assets to amounts expected to be realized. The accounting provisions related to uncertain income tax positions require the Company to determine whether any tax position in all open years meets a more likely than not threshold of being sustained upon examination by the applicable taxing authority. The Company did not have any changes to its liability for uncertain tax positions as at December 31, 2021 and 2020. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. No such amounts are accrued as of December 31, 2021 and 2020. The Company recognizes the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination. The Company recognizes interest and/or penalties related to uncertain tax positions. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected in the period that such determination is made. The interest and penalties are recognized as other expense and not tax expense. The Company currently has no interest and penalties related to uncertain tax positions.
Collateral Shares		Collateral Shares The Company accounts for the common shares issued as collateral for convertible promissory notes, whether upon original issuance or upon the required annual adjustment, as debt issuance costs in the form of a loan processing fee, which is determined by reference to the par value of the Company’s common stock, with a corresponding charge to operations when such collateral shares are issued. The collateral shares are subject to significant contractual restrictions limiting their sale or transfer. As these common shares have been issued to and are held by the lender, and are contingently returnable to the Company under certain conditions, such shares are considered as issued and outstanding on the Company’s balance sheet, but are not included in earnings per share calculations for all periods presented. In the event of an uncured event of default, the Company will record a charge to operations to recognize that the collateral shares are no longer owned or controlled by the Company, and such prospective charge to operations would be based on the fair market value of the collateral shares at that time, and which would be classified as a cost of debt capital and recognized as a charge to operations. As of December 31, 2021, all previously issued collateral shares have been returned to the common.
Loss per Common Share	Loss per Common Share The Company utilizes FASB ASC Topic No. 260, Earnings per Share 0 9,361,702 Since the effects of outstanding options, warrants, and the conversion of convertible debt are anti-dilutive for the period ended June 30, 2022 and 2021, shares of common stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of June 30, 2022 and 2021: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share June 30, 2022 2021 Warrants 1,827,650 33,304 Stock options 342,294 192,281 Convertible promissory notes - 4,996,476 Antidilutive securities, amount 2,169,944 5,222,061	Loss per Common Share The Company utilizes FASB ASC Topic No. 260, Earnings per Share 0 9,361,702 Since the effects of outstanding options, warrants, and the conversion of convertible debt are anti-dilutive for the years ended 2021 and 2020, shares of common stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of December 31, 2021 and 2020: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share December 31, 2021 2020 Warrants 1,827,650 91,841 Stock options 241,128 226,418 Convertible promissory notes - 4,684,872 2,068,778 5,003,131
New Accounting Standards	New Accounting Standards Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.	New Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon adoption of ASU 2020-06, convertible debt proceeds, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. ASU 2020-06 will be effective January 1, 2024, and a cumulative-effect adjustment to the opening balance of retained earnings is required upon adoption. Early adoption is permitted. We early adopted ASU 2020-06 on January 1, 2021, using the modified retrospective approach. Adoption of the new standard did not affect any previously reported amounts. Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.
Impact of the Novel Coronavirus (COVID-19) on the Company’s Business Operations	Impact of the Novel Coronavirus (COVID-19) on the Company’s Business Operations The global outbreak of the novel coronavirus (COVID-19) has led to severe disruptions in general economic activities worldwide, as businesses and governments have taken broad actions to mitigate this public health crisis. In light of the uncertain and continually evolving situation relating to the spread of COVID-19, this pandemic could pose a risk to the Company. The extent to which the coronavirus may impact the Company’s business operations will depend on future developments, which are highly uncertain and cannot be predicted at this time. The Company intends to continue to monitor the situation and may adjust its current business plans as more information and guidance become available. The coronavirus pandemic presents a challenge to medical facilities worldwide. As the Company’s clinical trials will be conducted on an outpatient basis, it is not currently possible to predict the full impact of this developing health crisis on such clinical trials, which could include delays in and increased costs of such clinical trials. Current indications from the clinical research organizations which will be conducting the clinical trials for the Company are that such clinical trials are being delayed or extended for several months as a result of the coronavirus pandemic. There is also significant uncertainty as to the effect that the coronavirus may have on the amount and type of financing available to the Company in the future.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of June 30, 2022 and 2021: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share June 30, 2022 2021 Warrants 1,827,650 33,304 Stock options 342,294 192,281 Convertible promissory notes - 4,996,476 Antidilutive securities, amount 2,169,944 5,222,061	The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of December 31, 2021 and 2020: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share December 31, 2021 2020 Warrants 1,827,650 91,841 Stock options 241,128 226,418 Convertible promissory notes - 4,684,872 2,068,778 5,003,131

Notes Payable - Related Party (

Notes Payable - Related Party (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Notes Payable	Schedule of Notes Payable Note Type Issue Date Maturity Date Interest Rate December 31, 2021 December 31, 2020 First Secured Convertible Note 10/24/14 12/31/21 8.5 % $ - $ 5,000,000 Second Secured Convertible Note 5/4/15 12/31/21 8.5 % - 2,000,000 Third Secured Convertible Note 2/24/16 12/31/21 8.5 % - 2,000,000 First Credit Facility 7/24/18 12/31/21 8.5 % - 2,000,000 Second Credit Facility 9/19/19 12/31/21 8.5 % - 712,179 Notes payable $ - $ 11,712,179

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Equity [Abstract]
Schedule of Warrant Activity	A summary of warrant activity for the period ended June 30, 2022 is presented below: Schedule of Warrant Activity Number of Weighted Weighted Subject to Exercise Warrants Price Life (Years) Outstanding as of December 31, 2021 1,827,650 $ 6.30 4.79 Granted – 2022 - - - Forfeited/Expired – 2022 - - - Exercised – 2022 - - - Outstanding as of June 30, 2022 1,827,650 $ 6.30 4.29	A summary of warrant activity for the years ended December 31, 2021 and 2020 are presented below: Schedule of Warrant Activity Subject to Exercise Number of Warrants Weighted Average Exercise Price Weighted Average Life (Years) Outstanding as of December 31, 2019 204,855 $ 12.64 1.40 Granted – 2020 - - - Forfeited/Expired – 2020 (113,014 ) - - Exercised – 2020 - - - Outstanding as of December 31, 2020 91,841 $ 14.88 0.34 Granted – 2021 1,827,650 6.30 5.00 Forfeited/Expired – 2021 (91,841 ) - - Exercised – 2021 - - - Outstanding as of December 31, 2021 1,827,650 $ 6.30 4.79
Schedule of Outstanding Vested and Unexercised Common Stock Warrants	As of June 30, 2022, the Company had outstanding vested and unexercised Common Stock Warrants as follows: Schedule of Outstanding Vested and Unexercised Common Stock Warrants Date Issued Exercise Price Number of Expiration date October 2021 $ 6.30 1,737,023 October 13, 2026 October 2021 $ 6.30 90,627 October 13, 2026 Total outstanding warrants at June 30, 2022 1,827,650	As of December 31, 2021, the Company had outstanding vested and unexercised Common Stock Warrants as follows: Schedule of Outstanding Vested and Unexercised Common Stock Warrants Date Issued Exercise Price Number of Warrants Expiration date October 2021 $ 6.30 1,737,023 October 13, 2026 October 2021 $ 6.30 90,627 October 13, 2026 Total outstanding warrants at December 31, 2021 1,827,650

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of stock option activity for the period ended June 30, 2022, is presented below: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Subject to Exercise Options Price Life (Years) Value Outstanding as of December 31, 2021 241,128 $ 32.76 5.43 $ 9,445 Granted – 2022 101,166 3.67 4.07 - Forfeited/Expired – 2022 - - - - Exercised – 2022 - - - - Outstanding as of June 30, 2022 342,294 $ 21.76 4.80 $ -	A summary of stock option activity for the years ended December 31, 2021 and 2020 are presented below: Schedule of Stock Option Activity Subject to Exercise Number of Options Weighted Average Exercise Price Weighted Average Life (Years) Aggregate Intrinsic Value Outstanding as of December 31, 2019 226,418 $ 41.08 6.56 $ - Granted – 2020 - - - - Forfeited/Expired – 2020 - - - - Exercised – 2020 - - - - Outstanding as of December 31, 2020 226,418 $ 37.00 4.65 $ - Outstanding as of December 31, 2020 226,418 $ 37.00 4.65 $ - Granted – 2021 48,847 4.24 10.00 - Forfeited/Expired – 2021 (34,137 ) 40.48 - - Exercised – 2021 - - - - Outstanding as of December 31, 2021 241,128 $ 32.76 5.43 $ 9,445
Schedule of Outstanding Stock Options	As of June 30, 2022, the Company had outstanding stock options as follows: Schedule of Outstanding Stock Options Date Issued Exercise Price Number of Expiration date August 2015 $ 39.75 41,624 December 27, 2025 September 2015 $ 39.75 8,000 December 27, 2025 November 2015 $ 39.75 48,986 December 27, 2025 December 2015 $ 39.75 2,228 December 27, 2025 January 2016 $ 39.75 51,032 January 9, 2026 May 2016 $ 51.25 10,766 May 26, 2026 September 2016 $ 51.25 3,973 May 31, 2026 January 2017 $ 51.25 2,142 January 1, 2027 January 2018 $ 49.25 1,566 January 1, 2028 January 2019 $ 2.35 21,964 January 1, 2029 October 2021 $ 5.25 48,847 October 26, 2031 January 2022 $ 3.52 26,166 January 1, 2032 January 2022 $ 3.72 50,000 January 1, 2024 January 2022 $ 3.72 25,000 January 3, 2024 Total outstanding options at June 30, 2022 342,294	As of December 31, 2021, the Company had outstanding stock options as follows: Schedule of Outstanding Stock Options Date Issued Exercise Price Number of Options Expiration date August 2015 $ 39.75 41,624 December 27, 2025 September 2015 $ 39.75 8,000 December 27, 2025 November 2015 $ 39.75 48,986 December 27, 2025 December 2015 $ 39.75 2,228 December 27, 2025 January 2016 $ 39.75 51,032 January 9, 2026 May 2016 $ 51.25 10,766 May 26, 2026 September 2016 $ 51.25 3,973 May 31, 2026 January 2017 $ 51.25 2,142 January 1, 2027 January 2018 $ 49.25 1,566 January 1, 2028 January 2019 $ 2.35 21,964 January 1, 2029 October 2021 $ 5.25 48,847 October 26, 2031 Total outstanding options at December 31, 2021 241,128
Schedule of Assumptions Using Black-Scholes Option Pricing Model	The Company utilized the Black-Scholes option-pricing model. The assumptions used for the periods ended June 30, 2022 and 2021 are as follows: Schedule of Assumptions Using Black-Scholes Option Pricing Model June 30, 2022 June 30, 2021 Risk free interest rate 0.39% 1.279 % - % Expected life (in years) 1.00 5.37 - Expected Volatility 96.24% 112.54 % - % Expected dividend yield - % - %	The Company utilized the Black-Scholes option-pricing model. The assumptions used for the years ended December 31, 2021 and 2020 are as follows: Schedule of Assumptions Using Black-Scholes Option Pricing Model December 31, 2021 December 31, 2020 Risk free interest rate 1.21 % - % Expected life (in years) 2 10 - Expected Volatility 113.93 % - % Expected dividend yield 0 % 0 %
Schedule of Stock Options Non-vested	A summary of the changes in the Company’s non-vested options during the six month period ended June 30, 2022, is as follows: Schedule of Stock Options Non-vested Number of Non- Weighted Average Non-vested at December 31, 2021 - $ - Granted in 2022 101,166 $ 1.77 Forfeited in 2022 - $ - Vested in 2022 (101,166 ) $ 1.77 Non-vested at June 30, 2022 - $ - Exercisable at June 30, 2022 342,294 $ 21.81 Outstanding at June 30, 2022 342,294 $ 21.81

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Taxes	The provision for income taxes consists of the following: Schedule of Provision for Income Taxes Year Ended December 31, 2021 December 31, 2020 Current: Federal $ - $ - State 1,600 1,600 Total current 1,600 1,600 Deferred: Federal - - State - - Total deferred - - Provision for income taxes $ 1,600 $ 1,600
Schedule of Deferred Tax Assets and Liabilities	The components of deferred tax assets and liabilities consist of the following: Schedule of Deferred Tax Assets and Liabilities December 31, 2021 December 31, 2020 Deferred tax assets Net operating losses $ 9,189,000 $ 8,749,000 Accrued expenses 693,000 693,000 R&D credits 624,000 619,000 Stock compensation 8,287,000 8,287,000 Total 18,793,000 18,348,000 Less: Valuation allowance (18,793,000 ) (18,348,000 ) Deferred tax assets $ - $ -
Schedule of Income Tax Effective Tax Rate	A reconciliation of the federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2021 and 2020 is as follows: Schedule of Income Tax Effective Tax Rate December 31, 2021 December 31, 2020 Statutory federal income tax rate 21.0 % 21.0 % State taxes, net of federal tax benefit 6.2 % 6.9 % Nondeductible permanent items (0.1 )% (0.2 )% Deferred tax rate change - % - % Research and development credit 0.3 % 1.2 % Change in valuation allowance (27.4 )% (28.9 )% Income tax provision 0.0 % 0.0 %

The Company (Details Narrative)

The Company (Details Narrative) - USD ($)			3 Months Ended				6 Months Ended		12 Months Ended
	Oct. 15, 2021	Oct. 12, 2021	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Stockholders' equity, reverse stock split		On October 12, 2021, an amendment to our certificate of incorporation for a reverse split of the Company’s outstanding common stock at a ratio of 1 for 2.5 became effective.
Retained earning accumulated deficit			$ 71,600,000				$ 71,600,000		$ 70,500,000
Operating expenses							9,500,000		6,500,000
Net income (loss)			$ 469,304	$ 689,499	$ 491,898	$ 431,747	1,158,803	$ 923,645	1,610,685	$ 1,824,690
Net cash used in operating activities							$ 1,220,843	$ 763,964	$ 1,228,586	$ 426,933
Common stock, par value			$ 0.001				$ 0.001		$ 0.001	$ 0.001
Proceeds from issuance of common stock									$ 6,858,843
Hankey Capital LLC [Member]
Ownership percentage			70%				70%		70%
Wallach Beth Capital LLC [Member]
Stock issued during period, shares, new issues	226,568
Hankey Capital LLC [Member]
Debt instrument face amount									$ 12,767,894
Interest payable current and noncurrent									$ 2,054,041
IPO [Member]
Sale of stock, number of shares issued in transaction	1,510,455
Common stock, par value	$ 0.001
Sale of stock, price per share	$ 5.25
Proceeds from issuance of common stock	$ 6,858,843
Proceeds from public offering	$ 6,858,843
IPO [Member] | Warrant [Member]
Shares issued, price per share	$ 6.30
Over-Allotment Option [Member] | Wallach Beth Capital LLC [Member]
Warrants and rights outstanding	$ 226,568
Class of warrant or right, number of securities called by warrants or rights	90,627
Class of warrant or right, exercise price of warrants or rights	$ 6.30
Percentage of toal offering	5%

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities, amount	2,169,944	5,222,061	2,068,778	5,003,131
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities, amount	1,827,650	33,304	1,827,650	91,841
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities, amount	342,294	192,281	241,128	226,418
Convertible Promissory Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities, amount		4,996,476		4,684,872

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cash uninsured amount			$ 250,000
Anti-dilutive securities outstanding excluded from computation of diluted net loss per share	2,169,944	5,222,061	2,068,778	5,003,131
Collateral Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities outstanding excluded from computation of diluted net loss per share	0	9,361,702	0	9,361,702

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Short-Term Debt [Line Items]
Secured Debt, Current		$ 11,712,179
First Secured Convertible Note [Member]
Short-Term Debt [Line Items]
Issue Date	Oct. 24, 2014
Maturity Date	Dec. 31, 2021
Interest Rate	8.50%
Secured Debt, Current		5,000,000
Second Secured Convertible Note [Member]
Short-Term Debt [Line Items]
Issue Date	May 04, 2015
Maturity Date	Dec. 31, 2021
Interest Rate	8.50%
Secured Debt, Current		2,000,000
Third Secured Convertible Note [Member]
Short-Term Debt [Line Items]
Issue Date	Feb. 24, 2016
Maturity Date	Dec. 31, 2021
Interest Rate	8.50%
Secured Debt, Current		2,000,000
First Credit Facility [Member]
Short-Term Debt [Line Items]
Issue Date	Jul. 24, 2018
Maturity Date	Dec. 31, 2021
Interest Rate	8.50%
Secured Debt, Current		2,000,000
Second Credit Facility [Member]
Short-Term Debt [Line Items]
Issue Date	Sep. 19, 2019
Maturity Date	Dec. 31, 2021
Interest Rate	8.50%
Secured Debt, Current		$ 712,179

Notes Payable - Related Party_2

Notes Payable - Related Party (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 02, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2019
Short-Term Debt [Line Items]
Interest payable related parties			$ 260,017		$ 510,840	$ 805,109	$ 998,076
Hankey Capital LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount						12,767,894
Interest payable						$ 2,054,041
Collateral shares, cancelled						9,361,702
Hankey Capital LLC [Member] | Second Credit Facility Convertible Secured Term Note [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price						$ 1
Line of credit facility, maximum borrowing capacity						$ 3,800,000
Proceeds from related party debt							2,712,179
Line of credit facility additional borrowing capacity						1,055,715
Hankey Capital LLC [Member] | All Outstanding Notes [Member]
Short-Term Debt [Line Items]
Interest payable related parties						0	1,251,626
Interest payable related parties						$ 805,109	998,076
Hankey Capital LLC [Member] | Minimum [Member] | Second Credit Facility Convertible Secured Term Note [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage						8.50%
Hankey Capital LLC [Member] | Prime Rate [Member] | Second Credit Facility Convertible Secured Term Note [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage						4%
First and Second Secured Convertible Notes and Warrants [Member] | Hankey Capital LLC [Member]
Short-Term Debt [Line Items]
Convertible notes payable, current							$ 9,000,000	$ 9,000,000
Debt maturity date	Dec. 31, 2021
Debt instrument, convertible, conversion price								$ 1
Number of shares of common stock issued as collateral						1,702,128	7,659,574
First and Second Secured Convertible Notes and Warrants [Member] | Hankey Capital LLC [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage								8.50%
First and Second Secured Convertible Notes and Warrants [Member] | Hankey Capital LLC [Member] | Prime Rate [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage								4%

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Number of warrents, outstanding, beginnig balance	1,827,650	91,841	204,855
Weighted average exercise price, outstanding, beginnig balance	6.30	14.88	12.64
Weighted average life, outstanding, beginning balance	4 years 9 months 14 days		1 year 4 months 24 days
Number of warrents, granted		1,827,650
Weighted average exercise price, granted		6.30
Number of warrents, forfeited		(91,841)	(113,014)
Weighted average exercise price, forfeited
Number of warrents, exercised
Weighted average exercise price, exercised
Weighted average life, outstanding, ending balance	4 years 3 months 14 days	4 years 9 months 14 days	4 months 2 days
Weighted average life, granted		5 years
Number of warrents, outstanding, ending balance	1,827,650	1,827,650	91,841
Weighted average exercise price, outstanding, ending balance	6.30	6.30	14.88

Schedule of Outstanding Vested

Schedule of Outstanding Vested and Unexercised Common Stock Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Jun. 30, 2022	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total outstanding warrants	1,827,650	1,827,650	91,841	204,855
October 2021 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price	6.30
Total outstanding warrants	1,737,023	1,737,023
ExpirationDate	Oct. 13, 2026
Exercise price		$ 6.30
Expiration date		Oct. 13, 2026
October 2021 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price	6.30
Total outstanding warrants	90,627	90,627
ExpirationDate	Oct. 13, 2026
Exercise price		$ 6.30
Expiration date		Oct. 13, 2026

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - USD ($)		12 Months Ended
	Oct. 15, 2021	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2022
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized		20,000,000	20,000,000	20,000,000
Preferred stock, shares issued		0	0	0
Common stock, shares authorized		100,000,000	100,000,000	100,000,000
Common stock, shares outstanding		10,350,574	12,273,036	10,350,579
Common stock, par value		$ 0.001	$ 0.001	$ 0.001
Proceeds from issuance of common stock		$ 6,858,843
Debt conversion converted instrument amount		$ 5,928,774
Stock repurchased and retired during period shares		9,361,702
Fair market value		$ 3.52		$ 1.40
Wallach Beth Capital LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued during period, shares, new issues	226,568
Hankey Capital LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Debt instrument face amount		$ 12,767,894
Interest payable current and noncurrent		$ 2,054,041
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction	1,510,455
Common stock, par value	$ 0.001
Sale of stock price per share	$ 5.25
Proceeds from issuance of common stock	$ 6,858,843
IPO [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued, price per share	$ 6.30
Over-Allotment Option [Member] | Wallach Beth Capital LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants and rights outstanding	$ 226,568
Class of warrant or right, number of securities called by warrants or rights	90,627
Class of warrant or right, exercise price of warrants or rights	$ 6.30
Percentage of toal offering	5%

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]
Number of Options Outstanding, Beginning balance	241,128	226,418	226,418
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 32.76	$ 37	$ 41.08
Weighted Average Life (Years), Outstanding, Ending balance	4 years 9 months 18 days	4 years 7 months 24 days	6 years 6 months 21 days
Aggregate Intrinsic Value, Outstanding, Beginning balance	$ 9,445
Number of Options, Granted	101,166	48,847
Weighted Average Exercise Price, Granted	$ 3.67	$ 4.24
Weighted Average Life (Years), Granted	4 years 25 days	10 years
Number of Options, Forfeited/Expired		(34,137)
Weighted Average Exercise Price, Forfeited/Expired		$ 40.48
Number of Options, Exercised
Weighted Average Exercise Price, Exercised
Number of Options Outstanding, Ending Balance	342,294	241,128	226,418
Weighted Average Exercise Price, Outstanding, Ending Balance	$ 21.76	$ 32.76	$ 37
Weighted Average Life (Years), Outstanding, ending balance		5 years 5 months 4 days	4 years 7 months 24 days
Aggregate Intrinsic Value, Outstanding, Ending Balance		$ 9,445
Weighted Average Life (Years), Outstanding, Beginning balance		5 years 5 months 4 days
Number of Options, Forfeited/Expired		34,137

Schedule of Outstanding Stock O

Schedule of Outstanding Stock Options (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options	342,294	241,128
August 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 39.75	$ 39.75
Number of options	41,624	41,624
Expiration date	Dec. 27, 2025	Dec. 27, 2025
September 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 39.75	$ 39.75
Number of options	8,000	8,000
Expiration date	Dec. 27, 2025	Dec. 27, 2025
November 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 39.75	$ 39.75
Number of options	48,986	48,986
Expiration date	Dec. 27, 2025	Dec. 27, 2025
December 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 39.75	$ 39.75
Number of options	2,228	2,228
Expiration date	Dec. 27, 2025	Dec. 27, 2025
January 2016 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 39.75	$ 39.75
Number of options	51,032	51,032
Expiration date	Jan. 09, 2026	Jan. 09, 2026
May 2016 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 51.25	$ 51.25
Number of options	10,766	10,766
Expiration date	May 26, 2026	May 26, 2026
September 2016 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 51.25	$ 51.25
Number of options	3,973	3,973
Expiration date	May 31, 2026	May 31, 2026
January 2017 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 51.25	$ 51.25
Number of options	2,142	2,142
Expiration date	Jan. 01, 2027	Jan. 01, 2027
January 2018 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 49.25	$ 49.25
Number of options	1,566	1,566
Expiration date	Jan. 01, 2028	Jan. 01, 2028
January 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 2.35	$ 2.35
Number of options	21,964	21,964
Expiration date	Jan. 01, 2029	Jan. 01, 2029
October 2021 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 5.25	$ 5.25
Number of options	48,847	48,847
Expiration date	Oct. 26, 2031	Oct. 26, 2031
January Two Thousand Twenty Two [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 3.52
Number of options	26,166
Expiration date	Jan. 01, 2032
January Two Thousand Twenty Two [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 3.72
Number of options	50,000
Expiration date	Jan. 01, 2024
January Two Thousand Twenty Two [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 3.72
Number of options	25,000
Expiration date	Jan. 03, 2024

Schedule of Assumptions Using B

Schedule of Assumptions Using Black-Scholes Option Pricing Model (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk free interest rate			1.21%
Expected life (in years)
Expected Volatility			113.93%
Expected dividend yield			0%	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk free interest rate	0.39%
Expected life (in years)	1 year		2 years
Expected Volatility	96.24%
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk free interest rate	1.279%
Expected life (in years)	5 years 4 months 13 days		10 years
Expected Volatility	112.54%

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, granted	101,166		48,847
Fair value of stock option	$ 171,592		$ 207,035
Stock-based compensation expense	$ 171,592		$ 207,035
2015 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	560,000		560,000
Percentage of stock issued and outstanding	5%		5%
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost	0

Schedule of Provision for Incom

Schedule of Provision for Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Current:
Federal
State					1,600	1,600
Total current					1,600	1,600
Deferred:
Federal
State
Total deferred
Provision for income taxes			$ 1,600		$ 1,600	$ 1,600

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Net operating losses	$ 9,189,000	$ 8,749,000
Accrued expenses	693,000	693,000
R&D credits	624,000	619,000
Stock compensation	8,287,000	8,287,000
Total	18,793,000	18,348,000
Less: Valuation allowance	(18,793,000)	(18,348,000)
Deferred tax assets

Schedule of Income Tax Effectiv

Schedule of Income Tax Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	21%	21%
State taxes, net of federal tax benefit	6.20%	6.90%
Nondeductible permanent items	(0.10%)	(0.20%)
Deferred tax rate change
Research and development credit	0.30%	1.20%
Change in valuation allowance	(27.40%)	(28.90%)
Income tax provision	0%	0%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 29,662,000	$ 29,860,000
Deferred tax assets, valuation allowance	18,793,000	$ 18,348,000
Change in the valuation allowance	$ 445,000
Effective tax rate	0%	0%

Deferred Compensation (Details

Deferred Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from issuance of common stock	$ 6,858,843
Deferred compensation		252,500
Deferred compensations liability	45,000
Gain on forgiveness of deferred compensation	297,500
Employee [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred compensation	$ 297,500
October 2016 Note Purchase Agreement [Member] | Non-current Stockholders [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of earned eferred compensation	20%
Proceeds from issuance of common stock	$ 5,000,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
UCLA TDG [Member]
Product Liability Contingency [Line Items]
License commitment fee		$ 500,000		$ 500,000
Proceeds from private placement percentage		2%		2%
License Agreement [Member]
Product Liability Contingency [Line Items]
Maintenance fees		$ 10,000		$ 10,000
Percentage of commercial sale of product		3%		3%
License Agreement [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
License commitment fee		$ 10,000	$ 45,500	$ 45,500	$ 102,293
Diligence fee	$ 8,000,000
License Agreement [Member] | UCLA TDG [Member] | First Subject in Feasibility Study [Member]
Product Liability Contingency [Line Items]
License commitment fee		100,000		100,000
License Agreement [Member] | UCLA TDG [Member] | First Subject in Pivotal Study [Member]
Product Liability Contingency [Line Items]
License commitment fee		250,000		250,000
License Agreement [Member] | UCLA TDG [Member] | Pre-Market Approval of Licensed Product or Licensed Method [Member]
Product Liability Contingency [Line Items]
License commitment fee		500,000		500,000
License Agreement [Member] | UCLA TDG [Member] | First Commercial Sale of Licensed Product or Licensed Method [Member]
Product Liability Contingency [Line Items]
License commitment fee		$ 1,000,000		$ 1,000,000
License Agreement [Member] | UCLA TDG [Member] | Minimum [Member]
Product Liability Contingency [Line Items]
Percentage of commercial sale of product		10%		10%
License Agreement [Member] | UCLA TDG [Member] | Maximum [Member]
Product Liability Contingency [Line Items]
Percentage of commercial sale of product		20%		20%
License Agreement [Member] | Third Party [Member]
Product Liability Contingency [Line Items]
Royalty percentage reduced		0.333%		0.333%
License Agreement [Member] | First Commercial Sale [Member]
Product Liability Contingency [Line Items]
Royalty expenses		$ 50,000		$ 50,000
License Agreement [Member] | After First Commercial Sale [Member]
Product Liability Contingency [Line Items]
Royalty expenses		$ 250,000		$ 250,000
License Agreement [Member] | Scenario One [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
Cumulative net sales description		Due upon cumulative Net Sales equaling $50,000,000 following the Triggering Sale Date - $2,000,000
License Agreement [Member] | Scenario Two [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
Cumulative net sales description		Due upon cumulative Net Sales equaling $100,000,000 following the Triggering Sale Date - $2,000,000
License Agreement [Member] | Scenario Three [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
Cumulative net sales description		Due upon cumulative Net Sales equaling $200,000,000 following the Triggering Sale Date - $4,000,000

Schedule of Stock Options Non-v

Schedule of Stock Options Non-vested (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Subsequent Events [Abstract]
Number of non-vested options, beginning
Weighted average fair value at grant date, beginning | $ / shares
Number of non-vested options, grants	101,166
Weighted average fair value at grant date, grants | $ / shares	$ 1.77
Number of non-vested options, forfeited
Weighted average fair value at grant date, forfeited | $ / shares
Number of non-vested options, vested	(101,166)
Weighted average fair value at grant date, vested | $ / shares	$ 1.77
Number of non-vested options, ending
Weighted average fair value at grant date, ending | $ / shares
Number of non-vested options, exercisable	342,294
Weighted average fair value at grant date, exercisable	21.81
Number of non-vested options, outstanding	342,294
Weighted average fair value at grant date, outstanding | $ / shares	$ 21.81

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)			1 Months Ended
	Mar. 03, 2022	Jan. 03, 2022	Aug. 23, 2022	Jun. 30, 2022	Jan. 01, 2022	Dec. 31, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Common stock, shares issued				10,350,579		10,350,574	12,273,036
Share based compensation shares authorized under stock option plans exercise price range number of outstanding options				342,294		241,128
Subsequent Event [Member] | Equity Option [Member]
Subsequent Event [Line Items]
Stock issued during period non employee director compensation			36,845
Subsequent Event [Member] | Supply and Development Support Agreement [Member] | Musculoskeletal Transplant Foundation, Inc [Member]
Subsequent Event [Line Items]
Agreement effective period description	The Agreement is in effect for a period of five years and may be extended for one (1) or more years upon mutual agreement of the Company and MTF.
Ms.Walsh [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Officer base salary		$ 200,000
Annual target bonus		25%
Employment agreement, description		The annual bonus, if any, shall be paid on or before March 15th of the calendar year following the year in which it is considered earned. The actual annual bonus paid may be more or less than twenty-five percent (25%) of Ms. Walsh’s base salary
Common stock, shares issued		25,000
Mr.Frelick [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, shares issued					50,000
Director [Member]
Subsequent Event [Line Items]
Share based compensation shares authorized under stock option plans exercise price range number of outstanding options					26,166